Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Solid Tumor Malignancies: early-phase trial registry
11 of 12 indexed Solid Tumor Malignancies trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #1,429 of 28,707 conditions by registered trial count.
12 US clinical trials · 11 currently recruiting · #1,429 of 28,707 conditions by registered trial count
Solid Tumor Malignancies: 12 US clinical trials tracked, 11 recruiting.
Solid Tumor Malignancies is the subject of 12 registered US clinical trials on ClinicalTrials.gov, 11 of them currently open to new participants. 2 are in Phase 3-4 (later-stage) and 8 in Phase 1-2 (earlier-stage). The most active sponsor is Kumquat Biosciences, running 3 of these trials.
Enrollment posture brief
Registry condition solid-tumor-malignancies
OPEN 11 | RECR 92% | LATE 2 | EARLY 8 | RANK #1429 | SPON 3
Volume-matched condition peers
Nearest open-share peer: Spinal Cord Injury Cervical (92% recruiting · 13 trials)
Solid Tumor Malignancies lists 11 open slots (92% of 12 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Solid Tumor Malignancies on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Solid Tumor Malignancies is recruiting above its size-band peers.
11 of 12 indexed trials (91.7%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Solid Tumor Malignancies research.
Kumquat Biosciences accounts for 3 of 12 trials (25%). 10 distinct sponsors appear on at least one study for this condition label.
-
Typical Solid Tumor Malignancies enrolment sits around 150 participants.
Median target enrolment is 150 among the 12 trials that report a genuine target (sentinel values excluded). 5 of those (41.7%) plan for fewer than 100 participants.
-
Solid Tumor Malignancies research is mostly interventional.
12 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
12 total, page 1 of 1
PROGRESS: Precision Oncology Using Genomic Reflexive Evaluations for Study Selection and Survival
UNC Lineberger Comprehensive Cancer Center
NCT06896162
Safety and Preliminary Efficacy of VIR-5525 and VIR-5525 + Pembrolizumab in Participants With Locally Advanced or Metastatic Solid Tumors
Vir Biotechnology
NCT06960395
xDRIVE for Florida-based Cancer Patients
First Ascent Biomedical
NCT07167381
A Study to Evaluate the Safety, Pharmacokinetics and Efficacy of TJ101 in Patients With Advanced/Metastatic Solid Tumors
Phrontline Biopharma
NCT07181473
Trial to Evaluate irAEs With Different Standard of Care Dosing Strategies of Standard of Care Immunotherapies
University of Kansas Medical Center
NCT07174453
Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors
Tasca Therapeutics
NCT07030257
A Study to Investigate the Safety and Efficacy of KQB365 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies
Kumquat Biosciences
NCT06720987
A First-In-Human, Phase 1 Study Evaluating Oral TACC3 PPI Inhibitor, AO-252, in Advanced Solid Tumors With or Without Brain Metastases
A2A Pharmaceuticals
NCT06136884
A Study to Investigate the Safety and Efficacy of KQB168 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies
Kumquat Biosciences
NCT06994806
A Study to Investigate the Safety and Efficacy of KQB548 in Participants With Advanced Solid Malignancies
Kumquat Biosciences
NCT07207707
Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies
Rigel Pharmaceuticals
NCT07486713
ProAgio in Previously Treated Advanced Pancreatic Cancer and Other Solid Tumor Malignancies
ProDa BioTech
NCT05085548
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 8 |
| Phase 3 | 1 |
| Phase 4 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Solid Tumor Malignancies records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Solid Tumor Malignancies trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Solid Tumor Malignancies page
12 registered trials, 11 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 11 Solid Tumor Malignancies trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Kumquat Biosciences sponsors the most Solid Tumor Malignancies trials on record, review their full trial history before evaluating a specific study. See Kumquat Biosciences's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Solid Tumor Malignancies condition card totals 12 registered trials; most-linked intervention Pembrolizumab; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.